Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2288-8586
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib ; volume:39 ; number:1 ; day:5 ; month:12 ; year:2017 ; pages:1-6 ; date:12.2017
Maxillofacial plastic and reconstructive surgery ; 39, Heft 1 (5.12.2017), 1-6, 12.2017
- Urheber
-
Bombeccari, Gian Paolo
- Beteiligte Personen und Organisationen
-
Garagiola, Umberto
Pallotti, Francesco
Rossi, Margherita
Porrini, Massimo
Giannì, Aldo Bruno
Spadari, Francesco
SpringerLink (Online service)
- DOI
-
10.1186/s40902-017-0136-y
- URN
-
urn:nbn:de:1111-2018011112403
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bombeccari, Gian Paolo
- Garagiola, Umberto
- Pallotti, Francesco
- Rossi, Margherita
- Porrini, Massimo
- Giannì, Aldo Bruno
- Spadari, Francesco
- SpringerLink (Online service)
Ähnliche Objekte (12)
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hairy-cell leukaemia
Hairy cell leukaemia
Soft tissue chondroma of hard palate associated with cleft palate
The cleft palate story
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial
Search for deletion 22q11.2 in interphase nuclei of buccal mucosa of patients ascertained by isolated cleft palate : a new diagnostic approach
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hairy-cell leukaemia
Hairy cell leukaemia
Soft tissue chondroma of hard palate associated with cleft palate
The cleft palate story
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial
Search for deletion 22q11.2 in interphase nuclei of buccal mucosa of patients ascertained by isolated cleft palate : a new diagnostic approach
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hairy-cell leukaemia
Hairy cell leukaemia
Soft tissue chondroma of hard palate associated with cleft palate
The cleft palate story
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial